Mn Services Vermogensbeheer B.V. Purchases New Holdings in Ionis Pharmaceuticals Inc (NASDAQ:IONS)

Mn Services Vermogensbeheer B.V. purchased a new stake in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 22,500 shares of the company’s stock, valued at approximately $1,446,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Buffington Mohr McNeal bought a new position in Ionis Pharmaceuticals during the first quarter valued at $28,000. Whittier Trust Co. grew its holdings in Ionis Pharmaceuticals by 283.0% during the second quarter. Whittier Trust Co. now owns 383 shares of the company’s stock valued at $25,000 after purchasing an additional 283 shares during the period. First Interstate Bank bought a new position in Ionis Pharmaceuticals during the first quarter valued at $34,000. Ellis Investment Partners LLC bought a new position in Ionis Pharmaceuticals during the second quarter valued at $32,000. Finally, Quadrant Capital Group LLC grew its holdings in Ionis Pharmaceuticals by 2,839.1% during the first quarter. Quadrant Capital Group LLC now owns 676 shares of the company’s stock valued at $53,000 after purchasing an additional 653 shares during the period. 83.17% of the stock is owned by institutional investors.

Several brokerages have weighed in on IONS. BMO Capital Markets reduced their price objective on Ionis Pharmaceuticals from $96.00 to $95.00 and set an “outperform” rating for the company in a report on Wednesday, July 24th. Zacks Investment Research lowered Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 31st. TheStreet lowered Ionis Pharmaceuticals from a “b-” rating to a “c” rating in a report on Thursday. Piper Jaffray Companies set a $75.00 price target on Ionis Pharmaceuticals and gave the stock a “hold” rating in a report on Friday, May 24th. Finally, ValuEngine lowered Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 18th. Nine equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $67.78.

In related news, Director Spencer R. Berthelsen sold 15,000 shares of Ionis Pharmaceuticals stock in a transaction on Monday, June 24th. The stock was sold at an average price of $63.67, for a total transaction of $955,050.00. Following the completion of the sale, the director now owns 99,404 shares of the company’s stock, valued at $6,329,052.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Stanley T. Crooke sold 10,000 shares of Ionis Pharmaceuticals stock in a transaction on Thursday, July 18th. The shares were sold at an average price of $70.25, for a total value of $702,500.00. Following the sale, the chief executive officer now directly owns 79,634 shares of the company’s stock, valued at approximately $5,594,288.50. The disclosure for this sale can be found here. Insiders have sold 40,210 shares of company stock valued at $2,650,844 in the last three months. 2.40% of the stock is owned by corporate insiders.

Ionis Pharmaceuticals stock opened at $68.44 on Friday. Ionis Pharmaceuticals Inc has a one year low of $43.27 and a one year high of $86.58. The stock has a fifty day moving average of $65.43. The company has a quick ratio of 9.36, a current ratio of 9.40 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $9.50 billion, a price-to-earnings ratio of 23.12 and a beta of 2.07.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.26. The company had revenue of $164.00 million during the quarter, compared to analyst estimates of $145.31 million. Ionis Pharmaceuticals had a return on equity of 41.41% and a net margin of 49.90%. The firm’s quarterly revenue was up 39.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.29) earnings per share. On average, research analysts forecast that Ionis Pharmaceuticals Inc will post -0.2 earnings per share for the current year.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Read More: Leveraged Buyout (LBO)

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.